Subscribe to RSS
DOI: 10.1055/s-0038-1667028
Practice Variation in Antenatal Steroid Administration for Anticipated Late Preterm Birth: A Physician Survey
Funding Financial support for this study was provided in part by Grant UA6MC19010 from the Maternal and Child Health Bureau of the Health Resources and Services Administration.Publication History
08 May 2018
07 June 2018
Publication Date:
17 July 2018 (online)
Abstract
Objective The objective of this study was to measure knowledge and practice variation in late preterm steroid use.
Study Design Electronic survey of American College of Obstetricians and Gynecologists (ACOG) members about data supporting the ACOG/Society for Maternal-Fetal Medicine (SMFM) recommendations and practice when caring for women with anticipated late preterm birth (PTB), 340/7 to 366/7 weeks.
Results Of 352 administered surveys, we obtained 193 completed responses (55%); 82.5% were generalist obstetrician-gynecologists (OB/GYNs), and 42% cared for women with anticipated late PTB at least weekly. Most believed that late preterm steroids provided benefit by reducing respiratory distress syndrome (93%), transient tachypnea of the newborn (83%), and neonatal intensive care unit admission (82%). More than half administered late preterm steroids to women with multiple gestations (73%), and pregestational diabetes (55–80%) depending on glycemic control. OB/GYNs administered steroids to insulin-dependent and poorly controlled diabetics more often than MFMs (75 vs. 46% and 59 vs. 37% respectively, p < 0.05 for both). While providers believed there was increased maternal hyperglycemia (88%) and neonatal hypoglycemia (59%), 88% believed neonatal respiratory benefits outweighed these risks. Respondents agreed research is needed to determine who are appropriate candidates (77%) and how to minimize adverse outcomes (82%).
Conclusion Most providers are administering late preterm steroids to all women, even those populations who have been excluded from previous trials. Despite widespread use, providers believe more research is needed to optimize management.
Note
This study was presented in poster format at the 38th annual meeting of the Society for Maternal-Fetal Medicine, Dallas, TX, January 29–February 3.
-
References
- 1 McIntire DD, Leveno KJ. Neonatal mortality and morbidity rates in late preterm births compared with births at term. Obstet Gynecol 2008; 111 (01) 35-41
- 2 Gyamfi-Bannerman C, Thom EA, Blackwell SC. , et al; NICHD Maternal–Fetal Medicine Units Network. Antenatal betamethasone for women at risk for late preterm delivery. N Engl J Med 2016; 374 (14) 1311-1320
- 3 Gynecologists ACoOa. ACOG Committee Opinion No. 677: antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 2016; 128: 187-194
- 4 Liggins GC, Howie RN. A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 1972; 50 (04) 515-525
- 5 NIH Consensus Development Panel on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. Effect of corticosteroids for fetal maturation on perinatal outcomes. JAMA 1995; 273 (05) 413-418
- 6 Crowley PA. Antenatal corticosteroid therapy: a meta-analysis of the randomized trials, 1972 to 1994. Am J Obstet Gynecol 1995; 173 (01) 322-335
- 7 Leviton LC, Goldenberg RL, Baker CS. , et al. Methods to encourage the use of antenatal corticosteroid therapy for fetal maturation: a randomized controlled trial. JAMA 1999; 281 (01) 46-52
- 8 Veloski J, Tai S, Evans AS, Nash DB. Clinical vignette-based surveys: a tool for assessing physician practice variation. Am J Med Qual 2005; 20 (03) 151-157